A Phase 3 clinical trial studying dulaglutide was listed as recruiting as of August 7, 2026. The study, registered as NCT06739122 and titled "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)," is evaluating the compound in pediatric participants with type 2 diabetes mellitus.
According to the trial registry, the study is currently in the recruiting phase and has not yet reported results. The listing specifies two dose levels under investigation, 3.0 mg and 4.5 mg, within this pediatric population. No outcome data, efficacy findings, or safety conclusions have been posted for this trial at this time.
Dulaglutide is an approved compound, and this trial represents an ongoing effort to study its use specifically in pediatric patients with type 2 diabetes. Further updates to the trial status, including any changes to enrollment or the eventual posting of results, would be reflected in future registry updates. Readers interested in following this trial can refer to the ClinicalTrials.gov listing for the most current status.
For more background on this compound, see the linked compound overview.